United Therapeutics (NASDAQ:UTHR) Price Target Raised to $344.00

United Therapeutics (NASDAQ:UTHR) had its price target raised by LADENBURG THALM/SH SH from $319.00 to $344.00 in a research report released on Thursday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

UTHR has been the subject of several other reports. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. UBS Group boosted their price target on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday. Finally, TD Cowen boosted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Up 0.0 %

Shares of NASDAQ:UTHR opened at $374.02 on Thursday. United Therapeutics has a 12-month low of $208.62 and a 12-month high of $377.92. The stock has a market cap of $16.70 billion, a PE ratio of 16.43, a P/E/G ratio of 1.35 and a beta of 0.56. The business has a 50 day moving average of $355.40 and a 200-day moving average of $316.65.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.38 earnings per share. Equities research analysts expect that United Therapeutics will post 24.85 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $325.45, for a total transaction of $1,171,620.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $42,308.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $325.45, for a total transaction of $1,171,620.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $42,308.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,412 shares of company stock worth $33,971,508. Corporate insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. LSV Asset Management increased its holdings in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the period. Swedbank AB acquired a new stake in United Therapeutics in the first quarter valued at $97,316,000. Nordea Investment Management AB increased its holdings in United Therapeutics by 677.6% in the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after purchasing an additional 262,222 shares during the period. Canada Pension Plan Investment Board increased its holdings in United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after purchasing an additional 153,700 shares during the period. Finally, Assetmark Inc. increased its holdings in United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.